A Phase 2A, Double Blind, Placebo controlled study of RSLV-132 in subjects with Systemic Lupus Erythematosus (SLE)

What we are studying

Investigational drug trial to determine the effects of drug RSLV-132

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 70

Eligibility Criteria

  • Cutaneous manifestations of SLE
  • No changes to SLE medications in the 30 days prior to baseline
  • No severe/active CNS involvement at screening
  • No use of cyclophosphamide within 3 months of baseline
  • No use of steroids
  • No positive viral load test for Hepatitis B; Hepatitis C; or HIV at Screening
  • No pregnant or breastfeeding

What is involved

  • Please contact the Study Coordinator for more information


Please contact the Study Coordinator for more information

Contact Information

Study Coordinator
Judy Hooker
Principal Investigator
Francis Luk M.D.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.